No Data
No Data
Immunic to Participate in Scientific and Industry Conferences in May
Immunic Presses Ahead With MS Drug Despite Phase II Endpoint Miss
William Blair Maintains Immunic(IMUX.US) With Buy Rating
Immunic Price Target Raised to $22 From $19 at Brookline
Immunic's Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
Express News | D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target
Rockhoundj : nice and steady
will be best